It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

BTIG analyst Mark Massaro reiterated a Buy rating on MaxCyte (MXCT – Research Report) yesterday and set a price target of $8.00. Mark ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...